Guardant Health has developed a system and method for detecting rare mutations and copy number variations in cell-free polynucleotides. The method involves sequencing cell-free nucleic acids from bodily fluids, using molecular barcodes for accurate detection, and applying bioinformatics tools for analysis. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Guardant Health Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of February 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Method for sequencing rare mutations in cell-free polynucleotides

Source: United States Patent and Trademark Office (USPTO). Credit: Guardant Health Inc

A recently granted patent (Publication Number: US11913065B2) discloses a method for sequencing polynucleotides derived from cell-free nucleic acids in a subject's sample. The method involves ligating the nucleic acids with molecular barcodes, amplifying them, and sequencing a subset to generate sequencing reads. The molecular barcodes are attached to at least 20% of the nucleic acids, and the process allows for the detection of sequences from both the barcodes and the nucleic acids.

The method described in the patent is applicable to various sample types such as blood, plasma, urine, and saliva. It is particularly useful for subjects with cancer or suspected of having cancer. The cell-free nucleic acids can be of different types, including DNA, RNA, and cfDNA. The use of molecular barcodes in excess amounts and specific ligation techniques ensures efficient tagging of the nucleic acids for sequencing. Additionally, the method allows for selective enrichment of specific genomic regions of interest, such as KRAS, APC, or TP53, prior to sequencing, enhancing the detection of relevant sequences in the sample. Overall, the patented method offers a comprehensive approach to sequencing cell-free nucleic acids with high accuracy and sensitivity, making it a valuable tool in molecular diagnostics and research.

To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.